

# Ansgar W Lohse

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6617648/publications.pdf>

Version: 2024-02-01

199  
papers

12,241  
citations

31976

53  
h-index

29157

104  
g-index

203  
all docs

203  
docs citations

203  
times ranked

12021  
citing authors

#	ARTICLE	IF	CITATIONS
1	Predictors of somatic symptom burden in healthcare professionals during the COVID-19 pandemic: an 8-week follow-up study. <i>Journal of Mental Health</i> , 2023, 32, 1111-1121.	1.9	4
2	Prevalence and risk factors of undiagnosed diabetes mellitus among gastroenterological patients: a HbA1c-based single center experience – Prevalence of undiagnosed diabetes in gastroenterological patients. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1306-1313.	0.5	1
3	SARS-CoV2-specific Humoral and T-cell Immune Response After Second Vaccination in Liver Cirrhosis and Transplant Patients. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 162-172.e9.	4.4	113
4	Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2022, 75, 13-27.	7.3	16
5	Long-term outcome after living donor liver transplantation compared to donation after brain death in autoimmune liver diseases: Experience from the European Liver Transplant Registry. <i>American Journal of Transplantation</i> , 2022, 22, 626-633.	4.7	14
6	Low incidence of colonic complications after severe Shiga toxin-producing E. coli O104:H4 infection. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 1104-1110.	0.5	1
7	Advances in genetic, epigenetic and environmental aspects of rare liver diseases. <i>European Journal of Medical Genetics</i> , 2022, 65, 104411.	1.3	1
8	Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2022, 76, 841-849.	3.7	64
9	Persistent SOMATIC symptoms ACROSS diseases – from risk factors to modification: scientific framework and overarching protocol of the interdisciplinary SOMACROSS research unit (RU 5211). <i>BMJ Open</i> , 2022, 12, e057596.	1.9	33
10	Disturbed lipid and amino acid metabolisms in COVID-19 patients. <i>Journal of Molecular Medicine</i> , 2022, 100, 555-568.	3.9	42
11	Equal Efficacy and Safety Profile in Elderly Patients with Hepatocellular Carcinoma Receiving Palliative Treatment. <i>Cancers</i> , 2022, 14, 768.	3.7	1
12	Low antibody titers after second SARS-CoV-2 vaccination in patients with autoimmune hepatitis. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, .	0.5	0
13	SARS-CoV-2 vaccination response in patients with autoimmune hepatitis and autoimmune cholestatic liver disease. <i>United European Gastroenterology Journal</i> , 2022, 10, 319-329.	3.8	27
14	Consensus recommendations for histological criteria of autoimmune hepatitis from the International <scp>AIH</scp> Pathology Group. <i>Liver International</i> , 2022, 42, 1058-1069.	3.9	45
15	Diagnosis of abdominal tuberculosis by mini-laparoscopy. <i>Infection</i> , 2022, 50, 1049-1050.	4.7	4
16	Stop of proton-pump inhibitor treatment in patients with liver cirrhosis (STOPPIT): study protocol for a prospective, multicentre, controlled, randomized, double-blind trial. <i>Trials</i> , 2022, 23, 302.	1.6	5
17	B cells in autoimmune hepatitis: bystanders or central players?. <i>Seminars in Immunopathology</i> , 2022, 44, 411-427.	6.1	12
18	Histological spectrum of autoimmune hepatitis – reply to Fujiwara K. et al.. <i>Liver International</i> , 2022, 42, 1704-1705.	3.9	0

#	ARTICLE	IF	CITATIONS
19	Inflammatory type 2 conventional dendritic cells contribute to murine and human cholangitis. <i>Journal of Hepatology</i> , 2022, 77, 1532-1544.	3.7	5
20	Sequential Systemic Treatment in Advanced Hepatocellular Carcinoma Is Able to Prolong Median Survival to More than 3 Years in a Selected Real-World Cohort. <i>Visceral Medicine</i> , 2021, 37, 87-93.	1.3	6
21	Bilateral Hematothorax Without Hematemesis—An Unusual Presentation of Variceal Bleeding. <i>Hepatology</i> , 2021, 73, 1233-1235.	7.3	0
22	Update of the simplified criteria for autoimmune hepatitis: Evaluation of the methodology for immunoserological testing. <i>Journal of Hepatology</i> , 2021, 74, 312-320.	3.7	31
23	Next-Generation Immunosequencing Reveals Pathological T-Cell Architecture in Autoimmune Hepatitis. <i>Hepatology</i> , 2021, 73, 1436-1448.	7.3	25
24	Clinical and Radiological Characterization of Patients with Immobilizing and Progressive Stress Fractures in Methotrexate Osteopathy. <i>Calcified Tissue International</i> , 2021, 108, 219-230.	3.1	11
25	Aryl Hydrocarbon Receptor Activity in Hepatocytes Sensitizes to Hyperacute Acetaminophen-Induced Hepatotoxicity in Mice. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2021, 11, 371-388.	4.5	11
26	Reply to: “Both tacrolimus and mycophenylate mophetil should be considered second-line therapy for autoimmune hepatitis”. <i>Journal of Hepatology</i> , 2021, 74, 755-756.	3.7	2
27	Liver transplantation for acute-on-chronic liver failure predicts post-transplant mortality and impaired long-term quality of life. <i>Liver International</i> , 2021, 41, 574-584.	3.9	19
28	Seroprevalence of SARS-CoV-2 antibodies among hospital workers in a German tertiary care center: A sequential follow-up study. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 232, 113671.	4.3	37
29	Lower Levels of Transaminases but Higher Levels of Serum Creatinine in Patients with Acute Hepatitis E in Comparison to Patients with Hepatitis A. <i>Pathogens</i> , 2021, 10, 60.	2.8	11
30	Clonal expansion and activation of tissue-resident memory-like T <sub>H</sub> 17 cells expressing GM-CSF in the lungs of patients with severe COVID-19. <i>Science Immunology</i> , 2021, 6, .	11.9	125
31	SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies. <i>Viruses</i> , 2021, 13, 661.	3.3	27
32	Evolution of liver stiffness and post-treatment surveillance by liver elastography for HCV patients in the DAA era. <i>Scandinavian Journal of Gastroenterology</i> , 2021, 56, 840-848.	1.5	2
33	Diagnostic and Prognostic Value of miR-16, miR-146a, miR-192 and miR-221 in Exosomes of Hepatocellular Carcinoma and Liver Cirrhosis Patients. <i>Cancers</i> , 2021, 13, 2484.	3.7	23
34	Patient Characteristics and Clinical Course of COVID-19 Patients Treated at a German Tertiary Center during the First and Second Waves in the Year 2020. <i>Journal of Clinical Medicine</i> , 2021, 10, 2274.	2.4	19
35	Cardiovascular magnetic resonance demonstrates structural cardiac changes following transjugular intrahepatic portosystemic shunt. <i>Scientific Reports</i> , 2021, 11, 12719.	3.3	6
36	Performance of non-invasive fibrosis scores in non-alcoholic fatty liver disease with and without morbid obesity. <i>International Journal of Obesity</i> , 2021, 45, 2197-2204.	3.4	21

#	ARTICLE	IF	CITATIONS
37	Prevalence of COVID-19 in patients with autoimmune liver disease in Europe: A patient-oriented online survey. <i>United European Gastroenterology Journal</i> , 2021, 9, 797-808.	3.8	12
38	SARS-CoV-2 infection in patients with autoimmune hepatitis. <i>Journal of Hepatology</i> , 2021, 74, 1335-1343.	3.7	90
39	Leukocyte-Derived High-Mobility Group Box 1 Governs Hepatic Immune Responses to <i>Listeria monocytogenes</i> . <i>Hepatology Communications</i> , 2021, 5, 2104-2120.	4.3	3
40	Hepatitis E virus persists in the ejaculate of chronically infected men. <i>Journal of Hepatology</i> , 2021, 75, 55-63.	3.7	17
41	Single-cell atlas of hepatic T cells reveals expansion of liver-resident naive-like CD4+ T cells in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2021, 75, 414-423.	3.7	49
42	FXR antagonists as new agents for COVID19. , 2021, , .		1
43	Low SARS-CoV-2 infection rates and high vaccine-induced immunity among German healthcare workers at the end of the third wave of the COVID-19 pandemic. <i>International Journal of Hygiene and Environmental Health</i> , 2021, 238, 113851.	4.3	13
44	Mobile app requirements for patients with rare liver diseases: A single center survey for the ERN RARE-LIVER. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2021, 45, 101760.	1.5	1
45	Autoimmune hepatitis: from immunopathogenesis to diagnostic and therapeutic innovation. <i>Current Opinion in Gastroenterology</i> , 2021, 37, 86-90.	2.3	6
46	Improvement of renal function prior to liver transplantation is not associated with better long-term renal outcome or survival. <i>Annals of Hepatology</i> , 2021, 26, 100559.	1.5	4
47	No link between male infertility and HEV genotype 3 infection. <i>Gut</i> , 2020, 69, 1150-1151.	12.1	12
48	A System to Determine Risk of Osteoporosis in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 226-233.e3.	4.4	15
49	Alterations of the bile microbiome in primary sclerosing cholangitis. <i>Gut</i> , 2020, 69, 665-672.	12.1	80
50	Rapid Response to Treatment of Autoimmune Hepatitis Associated With Remission at 6 and 12 Months. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 1609-1617.e4.	4.4	25
51	Permanent immunosuppression in SLA/LP-positive autoimmune hepatitis is required although overall response and survival are similar. <i>Liver International</i> , 2020, 40, 368-376.	3.9	21
52	Second-line and third-line therapy for autoimmune hepatitis: A position statement from the European Reference Network on Hepatological Diseases and the International Autoimmune Hepatitis Group. <i>Journal of Hepatology</i> , 2020, 73, 1496-1506.	3.7	55
53	Autoantibodies to intracellular $\alpha$ -ceroids and rings-structures in two patients with autoimmune hepatitis treated with azathioprine. <i>Autoimmunity</i> , 2020, 53, 362-365.	2.6	1
54	Review article: experimental therapies in autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1134-1149.	3.7	12

#	ARTICLE	IF	CITATIONS
55	Long-term outcome in PSC patients receiving azathioprine: Does immunosuppression have a positive effect on survival?. <i>Journal of Hepatology</i> , 2020, 73, 1285-1287.	3.7	3
56	Significance of Anti-Nuclear Antibodies and Cryoglobulins in Patients with Acute and Chronic HEV Infection. <i>Pathogens</i> , 2020, 9, 755.	2.8	7
57	Analysis of Co-inhibitory Receptor Expression in COVID-19 Infection Compared to Acute Plasmodium falciparum Malaria: LAG-3 and TIM-3 Correlate With T Cell Activation and Course of Disease. <i>Frontiers in Immunology</i> , 2020, 11, 1870.	4.8	45
58	Treatment and re-treatment results of HCV patients in the DAA era. <i>PLoS ONE</i> , 2020, 15, e0232773.	2.5	16
59	A disease-specific decline of the relative abundance of <i>Bifidobacterium</i> in patients with autoimmune hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1417-1428.	3.7	55
60	Risk factors for different intestinal pathogens among patients with traveler's diarrhea: A retrospective analysis at a German travel clinic (2009-2017). <i>Travel Medicine and Infectious Disease</i> , 2020, 37, 101706.	3.0	6
61	High discontinuation rate of azathioprine in autoimmune hepatitis, independent of time of treatment initiation. <i>Liver International</i> , 2020, 40, 2164-2171.	3.9	16
62	Characterization of the immune cell landscape of patients with NAFLD. <i>PLoS ONE</i> , 2020, 15, e0230307.	2.5	46
63	Autoimmune hepatitis: Possible triggers, potential treatments. <i>Journal of Hepatology</i> , 2020, 73, 446-448.	3.7	12
64	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. <i>Gastroenterology</i> , 2020, 159, 1417-1430.e3.	1.3	31
65	Anti-inflammatory microenvironment of esophageal adenocarcinomas negatively impacts survival. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1043-1056.	4.2	10
66	Longterm Survival After Liver Transplantation for Autoimmune Hepatitis: Results From the European Liver Transplant Registry. <i>Liver Transplantation</i> , 2020, 26, 866-877.	2.4	25
67	Monocytes as Potential Mediators of Pathogen-Induced T Helper 17 Differentiation in Patients With Primary Sclerosing Cholangitis (PSC). <i>Hepatology</i> , 2020, 72, 1310-1326.	7.3	50
68	Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial. <i>Lancet Infectious Diseases</i> , The, 2020, 20, 827-838.	9.1	125
69	Systemic interleukin 10 levels indicate advanced stages while interleukin 17A levels correlate with reduced survival in esophageal adenocarcinomas. <i>PLoS ONE</i> , 2020, 15, e0231833.	2.5	6
70	Management of patients with autoimmune liver disease during COVID-19 pandemic. <i>Journal of Hepatology</i> , 2020, 73, 453-455.	3.7	51
71	Bone microarchitecture in patients with autoimmune hepatitis. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 1316-1325.	2.8	3
72	Population-based study of autoimmune hepatitis and primary biliary cholangitis in Germany: rising prevalences based on ICD codes, yet deficits in medical treatment. <i>Zeitschrift Fur Gastroenterologie</i> , 2020, 58, 431-438.	0.5	17

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 15, e0231833.		0
74	Title is missing!. , 2020, 15, e0231833.		0
75	Title is missing!. , 2020, 15, e0231833.		0
76	Title is missing!. , 2020, 15, e0231833.		0
77	Lactate Improves Prediction of Shortâ€Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study. <i>Hepatology</i> , 2019, 69, 258-269.	7.3	83
78	The Clinical Perspective on Hepatitis E. <i>Viruses</i> , 2019, 11, 617.	3.3	85
79	HCV-specific CD4+ T cells of patients with acute and chronic HCV infection display high expression of TIGIT and other co-inhibitory molecules. <i>Scientific Reports</i> , 2019, 9, 10624.	3.3	27
80	Sex differences in clinical presentation and prognosis in patients with primary biliary cholangitis. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1391-1396.	1.5	8
81	Immediate versus deferred antiretroviral therapy in HIV-infected patients presenting with acute AIDS-defining events (toxoplasmosis, <i>Pneumocystis jirovecii</i> -pneumonia): a prospective, randomized, open-label multicenter study (IDEAL-study). <i>AIDS Research and Therapy</i> , 2019, 16, 34.	1.7	16
82	Transjugular Intrahepatic Portosystemic Shunt (TIPS) for primary and secondary prophylaxis of variceal bleeding in hepatic schistosomiasis. <i>Travel Medicine and Infectious Disease</i> , 2019, 30, 130-132.	3.0	9
83	Liver infiltrating T cells regulate bile acid metabolism in experimental cholangitis. <i>Journal of Hepatology</i> , 2019, 71, 783-792.	3.7	26
84	Ascites control by TIPS is more successful in patients with a lower paracentesis frequency and is associated with improved survival. <i>JHEP Reports</i> , 2019, 1, 90-98.	4.9	30
85	The burden of hepatitis E among patients with haematological malignancies: A retrospective European cohort study. <i>Journal of Hepatology</i> , 2019, 71, 465-472.	3.7	59
86	Chronic Hepatitis E is associated with cholangitis. <i>Liver International</i> , 2019, 39, 1876-1883.	3.9	16
87	Inflammatory Phenotype of Intrahepatic Sulfatide-Reactive Type II NKT Cells in Humans With Autoimmune Hepatitis. <i>Frontiers in Immunology</i> , 2019, 10, 1065.	4.8	16
88	Extended cycle streptozotocin/5-FU chemotherapy for maintenance therapy in pancreatic neuroendocrine tumors. <i>Endocrine</i> , 2019, 65, 460-467.	2.3	7
89	Predniso(lo)ne Dosage and Chance of Remission in Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2068-2075.e2.	4.4	55
90	Immunosuppression as effective therapy for eosinophilic cholangiopathy: A case series and review of the literature. <i>GastroHep</i> , 2019, 1, 33-44.	0.6	1

#	ARTICLE	IF	CITATIONS
91	Autoimmune hepatitis: Is the autoimmunity in the family?. <i>Liver International</i> , 2019, 39, 42-44.	3.9	1
92	Detectable Vesicular Stomatitis Virus (VSV)â€™Specific Humoral and Cellular Immune Responses Following VSVâ€™Ebola Virus Vaccination in Humans. <i>Journal of Infectious Diseases</i> , 2019, 219, 556-561.	4.0	29
93	Th17 cell frequency is associated with low bone mass in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , 2019, 70, 941-953.	3.7	27
94	Endoscopic retrograde cholangiography and percutaneous transhepatic cholangiodrainage in biliary strictures after liver transplantation: Longâ€™term outcome predictors and influence on patient survival. <i>Liver International</i> , 2019, 39, 1155-1164.	3.9	5
95	Hepatitis delta virus persists during liver regeneration and is amplified through cell division both in vitro and in vivo. <i>Gut</i> , 2019, 68, 150-157.	12.1	65
96	Disease Duration and Stage Influence Bone Microstructure in Patients With Primary Biliary Cholangitis. <i>Journal of Bone and Mineral Research</i> , 2018, 33, 1011-1019.	2.8	20
97	Hepatitis E seroprevalence in the Americas: A systematic review and metaâ€™analysis. <i>Liver International</i> , 2018, 38, 1951-1964.	3.9	44
98	Autoimmune hepatitis. <i>Nature Reviews Disease Primers</i> , 2018, 4, 18017.	30.5	280
99	Primary sclerosing cholangitis. <i>Lancet, The</i> , 2018, 391, 2547-2559.	13.7	276
100	Establishment of the First Well-differentiated Human Pancreatic Neuroendocrine Tumor Model. <i>Molecular Cancer Research</i> , 2018, 16, 496-507.	3.4	55
101	Time trend of reported cases and publications: hepatitis E in comparison to hepatitis Aâ€™SD in Germany from 2001 to 2016. <i>Zeitschrift Fur Gastroenterologie</i> , 2018, 56, 29-35.	0.5	2
102	HEV-positive blood donations represent a relevant infection risk for immunosuppressed recipients. <i>Journal of Hepatology</i> , 2018, 69, 36-42.	3.7	80
103	Usefulness of biochemical remission and transient elastography in monitoring disease course in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2018, 68, 754-763.	3.7	90
104	Proliferation of primary human hepatocytes and prevention of hepatitis B virus reinfection efficiently deplete nuclear cccDNA in vivo. <i>Gut</i> , 2018, 67, 542-552.	12.1	125
105	Autoimmune hepatitis: From current knowledge and clinical practice to future research agenda. <i>Liver International</i> , 2018, 38, 15-22.	3.9	71
106	Efficacy and Limitations of Budesonide as a Second-Line Treatment for Patients With Autoimmune Hepatitis. <i>Clinical Gastroenterology and Hepatology</i> , 2018, 16, 260-267.e1.	4.4	54
107	Fast and facile analysis of glycosylation and phosphorylation of fibrinogen from human plasmaâ€™correlation with liver cancer and liver cirrhosis. <i>Analytical and Bioanalytical Chemistry</i> , 2018, 410, 7965-7977.	3.7	12
108	Molecular and functional heterogeneity of IL-10-producing CD4+ T cells. <i>Nature Communications</i> , 2018, 9, 5457.	12.8	93

#	ARTICLE	IF	CITATIONS
109	Response for letter "Be cautious in comparing the seroprevalence of hepatitis E detected at different years in different countries". Liver International, 2018, 38, 2341-2341.	3.9	1
110	Inequity of care provision and outcome disparity in autoimmune hepatitis in the United Kingdom. Alimentary Pharmacology and Therapeutics, 2018, 48, 951-960.	3.7	34
111	Course of HEV viremia and anti-HEV IgM/IgG response in asymptomatic blood donors. Journal of Clinical Virology, 2018, 105, 26-30.	3.1	23
112	Epidemiology, clinical and laboratory features of 24 consecutive cases of leptospirosis at a German infectious disease center. Infection, 2018, 46, 847-853.	4.7	8
113	Variant syndromes of primary biliary cholangitis. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2018, 34-35, 55-61.	2.4	13
114	Patients with primary biliary cholangitis and fatigue present with depressive symptoms and selected cognitive deficits, but with normal attention performance and brain structure. PLoS ONE, 2018, 13, e0190005.	2.5	11
115	Comprehensive characterization of cellular immune responses following Ebola virus infection. Journal of Infectious Diseases, 2017, 215, jiw508.	4.0	38
116	Risk factors for excessively prolonged meropenem use in the intensive care setting: a case-control study. BMC Infectious Diseases, 2017, 17, 131.	2.9	5
117	TLR7-mediated activation of XBP1 correlates with the IFN $\gamma$ production in humans. Cytokine, 2017, 94, 55-58.	3.2	16
118	TIMP-1 is upregulated, but not essential in hepatic fibrogenesis and carcinogenesis in mice. Scientific Reports, 2017, 7, 714.	3.3	48
119	Can Understanding the Pathogenesis of Autoimmune Hepatitis Lead to Rational Therapy?. Digestive Diseases, 2017, 35, 367-370.	1.9	4
120	Hepatitis E virus: Infection beyond the liver?. Journal of Hepatology, 2017, 66, 1082-1095.	3.7	174
121	Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling. Journal of Hepatology, 2017, 66, 798-805.	3.7	26
122	Haem oxygenase-1 polymorphisms can affect HCV replication and treatment responses with different efficacy in humanized mice. Liver International, 2017, 37, 1128-1137.	3.9	8
123	Chronic pancreatitis in patients with liver cirrhosis negatively affects graft survival after liver transplantation. Pancreatology, 2017, 17, 898-904.	1.1	3
124	Systems Vaccinology Identifies an Early Innate Immune Signature as a Correlate of Antibody Responses to the Ebola Vaccine rVSV-ZEBOV. Cell Reports, 2017, 20, 2251-2261.	6.4	107
125	A Protective Function of IL-22BP in Ischemia Reperfusion and Acetaminophen-Induced Liver Injury. Journal of Immunology, 2017, 199, 4078-4090.	0.8	38
126	Autoimmune Hepatitis: When Is It Safe to Stop Therapy, or Withhold Therapy Altogether?. Current Hepatology Reports, 2017, 16, 113-118.	0.9	0



#	ARTICLE	IF	CITATIONS
127	High expression of micro RNA-135A in hepatocellular carcinoma is associated with recurrence within 12 months after resection. <i>BMC Cancer</i> , 2017, 17, 60.	2.6	24
128	CD4+ T cells from patients with primary sclerosing cholangitis exhibit reduced apoptosis and down-regulation of proapoptotic Bim in peripheral blood. <i>Journal of Leukocyte Biology</i> , 2017, 101, 589-597.	3.3	15
129	High Clinical Manifestation Rate in an Imported Outbreak of Hepatitis E Genotype 1 Infection in a German Group of Travellers Returning from India. <i>Annals of Hepatology</i> , 2017, 16, 57-62.	1.5	10
130	Autoimmune(-Like) Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1954.	4.1	39
131	Circulating tumor cells as liquid biomarker for high HCC recurrence risk after curative liver resection. <i>Oncotarget</i> , 2017, 8, 89978-89987.	1.8	58
132	Factors associated with long-term survival after liver transplantation: A retrospective cohort study. <i>World Journal of Hepatology</i> , 2017, 9, 427.	2.0	16
133	Hepatitis E Seroprevalence in Europe: A Meta-Analysis. <i>Viruses</i> , 2016, 8, 211.	3.3	188
134	Opposing role of tumor necrosis factor receptor 1 signaling in T cell-mediated hepatitis and bacterial infection in mice. <i>Hepatology</i> , 2016, 64, 508-521.	7.3	21
135	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , 2016, 63, 1357-1367.	7.3	133
136	The Development of Irritable Bowel Syndrome: A Prospective Community-Based Cohort Study. <i>American Journal of Gastroenterology</i> , 2016, 111, 1320-1329.	0.4	30
137	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1063-1064.	4.4	0
138	Variant Syndromes of Autoimmune Liver Diseases: Classification, Diagnosis and Management. <i>Digestive Diseases</i> , 2016, 34, 334-339.	1.9	17
139	Two Cases of Hepatosplenic T-Cell Lymphoma in Adolescents Treated for Autoimmune Hepatitis. <i>Pediatrics</i> , 2016, 138, .	2.1	8
140	Reduced CD161+ MAIT cell frequencies in HCV and HIV/HCV co-infection: Is the liver the heart of the matter?. <i>Journal of Hepatology</i> , 2016, 65, 1261-1263.	3.7	24
141	Nonalcoholic Fatty Liver Disease in Patients with Autoimmune Hepatitis: Further Reason for Teeth GNASHing?. <i>Digestive Diseases and Sciences</i> , 2016, 61, 2462-2464.	2.3	9
142	No Evidence That Azathioprine Increases Risk of Cholangiocarcinoma in Patients With Primary Sclerosing Cholangitis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1806-1812.	4.4	15
143	Diffusion-weighted MRI for detection of hepatic osteodystrophy in primary sclerosing cholangitis: a comparison study with dual-energy X-ray absorptiometry. <i>Japanese Journal of Radiology</i> , 2016, 34, 677-683.	2.4	3
144	Transient elastography in autoimmune hepatitis: Timing determines the impact of inflammation and fibrosis. <i>Journal of Hepatology</i> , 2016, 65, 769-775.	3.7	127

#	ARTICLE	IF	CITATIONS
145	Human liver chimeric mice as a new model of chronic hepatitis E virus infection and preclinical drug evaluation. <i>Journal of Hepatology</i> , 2016, 64, 1033-1040.	3.7	106
146	<i>Saccharomyces boulardii</i> to Prevent Antibiotic-Associated Diarrhea: A Randomized, Double-Masked, Placebo-Controlled Trial. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw011.	0.9	54
147	Acute Ebola virus disease patient treatment and health-related quality of life in health care professionals: A controlled study. <i>Journal of Psychosomatic Research</i> , 2016, 83, 69-74.	2.6	39
148	Efficacy of 6-Mercaptopurine as Second-Line Treatment for Patients With Autoimmune Hepatitis and Azathioprine Intolerance. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 445-453.	4.4	84
149	Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2016, 51, 329-336.	1.5	53
150	Phase 1 Trials of rVSV Ebola Vaccine in Africa and Europe. <i>New England Journal of Medicine</i> , 2016, 374, 1647-1660.	27.0	355
151	Validation of Transient Elastography and Comparison with Spleen Length Measurement for Staging of Fibrosis and Clinical Prognosis in Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2016, 11, e0164224.	2.5	45
152	Constitutive gp130 activation rapidly accelerates the transformation of human hepatocytes via an impaired oxidative stress response. <i>Oncotarget</i> , 2016, 7, 55639-55648.	1.8	3
153	Temoporfin improves efficacy of photodynamic therapy in advanced biliary tract carcinoma: A multicenter prospective phase II study. <i>Hepatology</i> , 2015, 62, 1456-1465.	7.3	56
154	Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure. <i>World Journal of Gastroenterology</i> , 2015, 21, 2214-2219.	3.3	14
155	Criteria Used in Clinical Practice to Guide Immunosuppressive Treatment in Patients with Primary Sclerosing Cholangitis. <i>PLoS ONE</i> , 2015, 10, e0140525.	2.5	8
156	Nanoparticle-based autoantigen delivery to Treg-inducing liver sinusoidal endothelial cells enables control of autoimmunity in mice. <i>Journal of Hepatology</i> , 2015, 62, 1349-1356.	3.7	145
157	Patient selection based on treatment duration and liver biochemistry increases success rates after treatment withdrawal in autoimmune hepatitis. <i>Journal of Hepatology</i> , 2015, 62, 642-646.	3.7	82
158	Autoimmune hepatitis " Update 2015. <i>Journal of Hepatology</i> , 2015, 62, S100-S111.	3.7	290
159	Testosterone Suppresses Hepatic Inflammation by the Downregulation of IL-17, CXCL-9, and CXCL-10 in a Mouse Model of Experimental Acute Cholangitis. <i>Journal of Immunology</i> , 2015, 194, 2522-2530.	0.8	50
160	Hepatitis Delta co-infection in humanized mice leads to pronounced induction of innate immune responses in comparison to HBV mono-infection. <i>Journal of Hepatology</i> , 2015, 63, 346-353.	3.7	104
161	Adjuvant chemotherapy with gemcitabine and cisplatin compared to observation after curative intent resection of cholangiocarcinoma and muscle invasive gallbladder carcinoma (ACTICCA-1 trial) - a randomized, multidisciplinary, multinational phase III trial. <i>BMC Cancer</i> , 2015, 15, 564.	2.6	182
162	CD4+ T-Cell Help Is Required for Effective CD8+ T Cell-Mediated Resolution of Acute Viral Hepatitis in Mice. <i>PLoS ONE</i> , 2014, 9, e86348.	2.5	28

#	ARTICLE	IF	CITATIONS
163	Matrix Conditions and KLF2-Dependent Induction of Heme Oxygenase-1 Modulate Inhibition of HCV Replication by Fluvastatin. <i>PLoS ONE</i> , 2014, 9, e96533.	2.5	17
164	Association of autoimmune hepatitis and systemic lupus erythematoses: A case series and review of the literature. <i>World Journal of Gastroenterology</i> , 2014, 20, 12662.	3.3	42
165	Long-term outcome in PSC/AIH "overlap syndrome": Does immunosuppression also treat the PSC component?. <i>Journal of Hepatology</i> , 2014, 61, 1189-1191.	3.7	33
166	Acute autoimmune hepatitis: Many open questions. <i>Journal of Hepatology</i> , 2014, 61, 727-729.	3.7	20
167	Autoimmune hepatitis on the rise. <i>Journal of Hepatology</i> , 2014, 60, 478-479.	3.7	19
168	Reduced FOXP3+ regulatory T cells in patients with primary sclerosing cholangitis are associated with IL2RA gene polymorphisms. <i>Journal of Hepatology</i> , 2014, 60, 1010-1016.	3.7	90
169	Genome-Wide Association Study Identifies Variants Associated With Autoimmune Hepatitis Type 1. <i>Gastroenterology</i> , 2014, 147, 443-452.e5.	1.3	268
170	Psychological Outcome, Fatigue, and Quality of Life After Infection With Shiga Toxin-Producing <i>Escherichia coli</i> O104. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1848-1855.	4.4	25
171	Transient Elastography in Primary Sclerosing Cholangitis: the Value as a Prognostic Factor and Limitations. <i>Gastroenterology</i> , 2014, 147, 542-543.	1.3	21
172	Reply to: "Anti-TNF-induced autoimmune hepatitis". <i>Journal of Hepatology</i> , 2014, 61, 170-171.	3.7	2
173	Persistent hepatitis D virus mono-infection in humanized mice is efficiently converted by hepatitis B virus to a productive co-infection. <i>Journal of Hepatology</i> , 2014, 60, 538-544.	3.7	74
174	TGF- $\beta$ -dependent induction of CD4+CD25+Foxp3+ Tregs by liver sinusoidal endothelial cells. <i>Journal of Hepatology</i> , 2014, 61, 594-599.	3.7	185
175	Immune cell responses are not required to induce substantial hepatitis B virus antigen decline during pegylated interferon-alpha administration. <i>Journal of Hepatology</i> , 2014, 60, 500-507.	3.7	68
176	Low Risk of Hepatocellular Carcinoma in Patients With Primary Sclerosing Cholangitis With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2014, 12, 1733-1738.	4.4	66
177	Increased T helper type 17 response to pathogen stimulation in patients with primary sclerosing cholangitis. <i>Hepatology</i> , 2013, 58, 1084-1093.	7.3	132
178	Infliximab as a rescue treatment in difficult-to-treat autoimmune hepatitis. <i>Journal of Hepatology</i> , 2013, 58, 529-534.	3.7	202
179	Diagnostic criteria for autoimmune hepatitis. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2011, 25, 665-671.	2.4	22
180	Overlap syndromes: The International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue. <i>Journal of Hepatology</i> , 2011, 54, 374-385.	3.7	470

#	ARTICLE	IF	CITATIONS
181	Rolls Royce for everybody? Diagnosing liver disease by mini-laparoscopy. <i>Journal of Hepatology</i> , 2011, 54, 584-585.	3.7	5
182	Autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 171-182.	3.7	170
183	Role of mycophenolate mofetil in the treatment of autoimmune hepatitis. <i>Journal of Hepatology</i> , 2011, 55, 510-511.	3.7	10
184	Treatment response in patients with autoimmune hepatitis. <i>Hepatology</i> , 2010, 52, 2247-2248.	7.3	47
185	Budesonide Induces Remission More Effectively Than Prednisone in a Controlled Trial of Patients With Autoimmune Hepatitis. <i>Gastroenterology</i> , 2010, 139, 1198-1206.	1.3	394
186	Immune tolerance: What is unique about the liver. <i>Journal of Autoimmunity</i> , 2010, 34, 1-6.	6.5	326
187	Reply:. <i>Hepatology</i> , 2009, 49, 1783-1783.	7.3	0
188	Characteristics and Long-term Prognosis of the Autoimmune Hepatitis/Primary Sclerosing Cholangitis Overlap Syndrome. <i>Journal of Clinical Gastroenterology</i> , 2009, 43, 75-80.	2.2	77
189	Simplified criteria for the diagnosis of autoimmune hepatitis. <i>Hepatology</i> , 2008, 48, 169-176.	7.3	1,553
190	Mycophenolate Mofetil as Second Line Therapy in Autoimmune Hepatitis?. <i>American Journal of Gastroenterology</i> , 2008, 103, 3063-3070.	0.4	179
191	Prospective Randomized Comparison of Minilaparoscopy and Percutaneous Liver Biopsy. <i>Journal of Clinical Gastroenterology</i> , 2007, 41, 103-110.	2.2	87
192	Defective T Helper Response of Hepatocyte-Stimulated CD4 T Cells Impairs Antiviral CD8 Response and Viral Clearance. <i>Gastroenterology</i> , 2007, 133, 2010-2018.	1.3	39
193	Evaluation of F-Actin ELISA for the Diagnosis of Autoimmune Hepatitis. <i>American Journal of Gastroenterology</i> , 2006, 101, 2731-2736.	0.4	82
194	Antibodies to soluble liver antigen/liver pancreas and HLA risk factors for type 1 autoimmune hepatitis. <i>American Journal of Gastroenterology</i> , 2002, 97, 413-419.	0.4	137
195	Fine specificity of autoantibodies to soluble liver antigen and liver/pancreas. <i>Hepatology</i> , 2002, 35, 403-408.	7.3	56
196	Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. <i>Lancet, The</i> , 2000, 355, 1510-1515.	13.7	318
197	Characterization of the overlap syndrome of primary biliary cirrhosis (PBC) and autoimmune hepatitis: Evidence for it being a hepatic form of PBC in genetically susceptible individuals. <i>Hepatology</i> , 1999, 29, 1078-1084.	7.3	259
198	Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. <i>Journal of Hepatology</i> , 1999, 31, 635-640.	3.7	142

#	ARTICLE	IF	CITATIONS
199	Combined Therapy with Azathioprine, Prednisolone, and Ursodiol in Patients with Primary Sclerosing Cholangitis: A Case Series. <i>Annals of Internal Medicine</i> , 1999, 131, 943.	3.9	96